Citigroup’s Belite Bio BLTE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-47
Closed -$7.24K – 6017
2026
Q2
$7.24K Buy
47
+46
+4,600% +$7.05K ﹤0.01% 5276
2026
Q1
$159 Sell
1
-2,136
-100% -$359K ﹤0.01% 5588
2025
Q4
$342K Sell
2,137
-1,873
-47% -$222K ﹤0.01% 3751
2025
Q3
$297K Buy
+4,010
New +$263K ﹤0.01% 3818
2025
Q2
– Sell
-3
Closed -$199 – 5658
2025
Q1
$199 Buy
+3
New +$181 ﹤0.01% 5414

Other funds holding BLTE

Citigroup's BLTE Position: Q3 2026 in Review

Citigroup sold out of Belite Bio (BLTE) in Q3 2026, closing a stake of 47 shares — an estimated $7.24K sold.

Citigroup first reported a position in BLTE in Q1 2025 and held it in 5 quarters. The position peaked at $342K in Q4 2025. 96 funds tracked by Wall St. Rank hold BLTE as of Q3 2026.

  • Citigroup reported no remaining Belite Bio position as of Q3 2026 after selling out during the quarter.
  • Citigroup sold 47 Belite Bio shares in Q3 2026, an estimated $7.24K.
  • Citigroup first reported a position in Belite Bio in Q1 2025 and held it in 5 quarters.
  • Citigroup's Belite Bio position peaked at $342K in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Belite Bio as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.